David Scholfield - Concepedia

Author

David Scholfield

Pfizer (United Kingdom)

Also Known As

D P Scholfield, D. P. Scholfield, D.P. Scholfield, David P. Scholfield, David Scholfield

Publications

438

Citations

H-Index

Concepts

All Affiliations

Pfizer (United Kingdom)Pfizer (United States)Queen's Medical Centre Nottingham City Hospital Sorbonne Université

About

David Scholfield is an author at Pfizer (United Kingdom) specializing in medicine, urology, and population.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	105
2	Public Health	1	1	50
3	Social Sciences	1	1	12
4	Epidemiology	1	1	50
5	Immunology	1	1	17

David Scholfield

Publications

348

Citations

H-Index

Page 1

	Year	Citations
Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer Matthew Simms, David Scholfield, Elizabeth R. Jacobs, British Journal of Cancer	2000	75
Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine Gary G. Kay, Paul Maruff, David Scholfield, Postgraduate Medicine	2012	64
Demographic diversity of participants in Pfizer sponsored clinical trials in the United States Melinda M. Rottas, Peter F. Thadeio, Rachel N. Simons, Contemporary Clinical Trials Health Care DisparityHealth DisparitiesPopulation SubgroupsUnited StatesRacial Disparities	2021	50
Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. Andrea Murray, Matthew Simms, David Scholfield, PubMed	2001	42
Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled <scp>EIGHT</scp> trial Christopher R. Chapple, Tim Schneider, François Haab, British Journal of Urology	2014	33
Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder Bimal Malhotra, Ahmed El‐Tahtawy, Ellen Q. Wang, Journal of Pediatric Urology UrologyVoiding DysfunctionMedicineDose-escalating StudyClinical Pharmacology	2012	26
Production and characterisation of a C595 antibody- 99m Tc conjugate for immunoscintigraphy of bladder cancer Matthew Simms, Andrea Murray, Graeme Denton, Urological Research Immunocytochemical TechniqueC595 Antibody- 99MGenitourinary CancerMedicineImmunology	2001	17
<sup>99m</sup> Technetium‐C595 radioimmunoscintigraphy: a potential staging tool for bladder cancer Matthew Simms, Alan C. Perkins, M.R. Price, British Journal of Urology	2001	15
Investigation of a Ca <sup>2+</sup> Channel α2δ Ligand for the Treatment of Interstitial Cystitis: Results of a Randomized, Double-Blind, Placebo Controlled Phase II Trial J. Curtis Nickel, Anna Crossland, Edward L. Davis, The Journal of Urology	2012	14
A PHASE 2, 8-WEEK, MULTI-CENTER, RANDOMIZED DOUBLE- BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY, TOLERABILITY AND SAFETY OF [S,S] - REBOXETINE (PNU-165442G) FOR STRESS URINARY INCONTINENCE IN WOMEN Norman R. Zinner, David Scholfield, Koshika Soma, The Journal of Urology Reproductive SciencesRandomized Double- BlindPelvic Reconstructive SurgeryGynecologyPopulation Health Sciences	2008	12

Page 1